A Randomized, Double-blind, Comparator-controlled Trial to Assess the Effect of 12-week Treatment With Dapagliflozin Versus Gliclazide on Renal Physiology and Biomarkers in Metformin-treated Patients With Type 2 Diabetes Mellitus

Trial Profile

A Randomized, Double-blind, Comparator-controlled Trial to Assess the Effect of 12-week Treatment With Dapagliflozin Versus Gliclazide on Renal Physiology and Biomarkers in Metformin-treated Patients With Type 2 Diabetes Mellitus

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 26 May 2017

At a glance

  • Drugs Dapagliflozin (Primary) ; Gliclazide
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 May 2017 Planned End Date changed from 1 May 2018 to 1 Oct 2018.
    • 19 May 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top